106 related articles for article (PubMed ID: 15829988)
1. PDE-5 inhibitor, Vardenafil, increases circulating progenitor cells in humans.
Foresta C; Lana A; Cabrelle A; Ferigo M; Caretta N; Garolla A; Palù G; Ferlin A
Int J Impot Res; 2005; 17(4):377-80. PubMed ID: 15829988
[TBL] [Abstract][Full Text] [Related]
2. Effect of vardenafil on endothelial progenitor cells in hypogonadotrophic hypogonadal patients: role of testosterone treatment.
Foresta C; Di Mambro A; Caretta N; De Toni L; Zuccarello D; Ferlin A
Clin Endocrinol (Oxf); 2009 Sep; 71(3):412-6. PubMed ID: 19094070
[TBL] [Abstract][Full Text] [Related]
3. Relationship between vascular damage degrees and endothelial progenitor cells in patients with erectile dysfunction: effect of vardenafil administration and PDE5 expression in the bone marrow.
Foresta C; Caretta N; Lana A; De Toni L; Biagioli A; Vinanzi C; Ferlin A
Eur Urol; 2007 May; 51(5):1411-7; discussion 1417-9. PubMed ID: 17034932
[TBL] [Abstract][Full Text] [Related]
4. [Therapeutic efficacy of a course administration of vardenafil--inhibitor of phosphodiesterase-5--in erectile dysfunction].
Aliaev IuG; Vinarov AZ; Akhvlediani ND
Urologiia; 2007; (1):45-6, 49. PubMed ID: 17471999
[TBL] [Abstract][Full Text] [Related]
5. [Levitra (vardenafil)--a new PDE 5 inhibitor for the treatment of erectile dysfunction].
Katsarov M
Akush Ginekol (Sofiia); 2004; 43 Suppl 1():31-2. PubMed ID: 15323315
[No Abstract] [Full Text] [Related]
6. Mechanism of Phosphodiesterase 5 inhibitor relief of prostatitis symptoms.
Grimsley SJ; Khan MH; Jones GE
Med Hypotheses; 2007; 69(1):25-6. PubMed ID: 17300876
[TBL] [Abstract][Full Text] [Related]
7. Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease.
Ravipati G; McClung JA; Aronow WS; Peterson SJ; Frishman WH
Cardiol Rev; 2007; 15(2):76-86. PubMed ID: 17303994
[TBL] [Abstract][Full Text] [Related]
8. Drug Insight: oral phosphodiesterase type 5 inhibitors for erectile dysfunction.
Briganti A; Salonia A; Gallina A; Saccà A; Montorsi P; Rigatti P; Montorsi F
Nat Clin Pract Urol; 2005 May; 2(5):239-47. PubMed ID: 16474835
[TBL] [Abstract][Full Text] [Related]
9. [New potency pill. Treating (vascular) bed failure].
MMW Fortschr Med; 2003 Jan; 145(5):51. PubMed ID: 12619215
[No Abstract] [Full Text] [Related]
10. Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms.
Tinel H; Stelte-Ludwig B; Hütter J; Sandner P
BJU Int; 2006 Dec; 98(6):1259-63. PubMed ID: 16956354
[TBL] [Abstract][Full Text] [Related]
11. Epistaxis after PDE-5 inhibitors misuse.
Pomara G; Morelli G; Menchini-Fabris F; Dinelli N; Campo G; LiGuori G; Selli C
Int J Impot Res; 2006; 18(2):213-4. PubMed ID: 16107867
[TBL] [Abstract][Full Text] [Related]
12. Time-dependent involvement of cAMP and cGMP in consolidation of object memory: studies using selective phosphodiesterase type 2, 4 and 5 inhibitors.
Rutten K; Prickaerts J; Hendrix M; van der Staay FJ; Sik A; Blokland A
Eur J Pharmacol; 2007 Mar; 558(1-3):107-12. PubMed ID: 17207788
[TBL] [Abstract][Full Text] [Related]
13. [Levitra (wardenafil) effects on endothelial function of brachial and cavernous arteries].
Mazo EB; Gamidov SI; Ovchinnikov RI; Adranovich SV; Iremashvili VV
Urologiia; 2008; (5):43-4, 46-7. PubMed ID: 19069495
[TBL] [Abstract][Full Text] [Related]
14. Systemic administration of phosphodiesterase V inhibitor, sildenafil citrate, for attenuation of cerebral vasospasm after experimental subarachnoid hemorrhage.
Atalay B; Caner H; Cekinmez M; Ozen O; Celasun B; Altinors N
Neurosurgery; 2006 Nov; 59(5):1102-7; discussion 1107-8. PubMed ID: 17143244
[TBL] [Abstract][Full Text] [Related]
15. Evidence for contamination of herbal erectile dysfunction products with phosphodiesterase type 5 inhibitors.
Fleshner N; Harvey M; Adomat H; Wood C; Eberding A; Hersey K; Guns E
J Urol; 2005 Aug; 174(2):636-41; discussion 641; quiz 801. PubMed ID: 16006928
[TBL] [Abstract][Full Text] [Related]
16. Vardenafil enhances clitoral and vaginal blood flow responses to pelvic nerve stimulation in female dogs.
Angulo J; Cuevas P; Cuevas B; Bischoff E; Sáenz de Tejada I
Int J Impot Res; 2003 Apr; 15(2):137-41. PubMed ID: 12789394
[TBL] [Abstract][Full Text] [Related]
17. [Phosphodiesterase 5 inhibition in erectile dysfunction. Long-term administration without therapeutic advantage].
MMW Fortschr Med; 2009 Jan; 151(1-2):50-1. PubMed ID: 19227645
[No Abstract] [Full Text] [Related]
18. Prescribing all phosphodiesterase 5 inhibitors to a patient with erectile dysfunction--a realistic and feasible option in everyday clinical practice--outcomes of a simple treatment regime.
Ströberg P; Hedelin H; Ljunggren C
Eur Urol; 2006 May; 49(5):900-7; discussion 907. PubMed ID: 16564126
[TBL] [Abstract][Full Text] [Related]
19. Long-term therapy of interferon-alpha induced pulmonary arterial hypertension with different PDE-5 inhibitors: a case report.
Jochmann N; Kiecker F; Borges AC; Hofmann MA; Eddicks S; Sterry W; Baumann G; Trefzer U
Cardiovasc Ultrasound; 2005 Sep; 3():26. PubMed ID: 16138923
[TBL] [Abstract][Full Text] [Related]
20. [Systemic approach to investigation of levitra efficacy in patients with chronic prostatitis with erectile dysfunction].
Aliaev IuG; Ronkin MA; Esilevskiĭ IuM; Zhuchenko TD; Demidko IuL; Krupinov GE; Shcherbanina VIu
Urologiia; 2005; (2):53-60. PubMed ID: 15989030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
